Pinnacle Wealth Management Advisory Group Lowers stake in Bristol-Myers Squibb Co (BMY)

Bristol-Myers Squibb Co (BMY) : Pinnacle Wealth Management Advisory Group reduced its stake in Bristol-Myers Squibb Co by 1.0% during the most recent quarter end. The investment management company now holds a total of 18,882 shares of Bristol-Myers Squibb Co which is valued at $1.3 Million after selling 190 shares in Bristol-Myers Squibb Co , the firm said in a disclosure report filed with the SEC on May 12, 2016.Bristol-Myers Squibb Co makes up approximately 1.19% of Pinnacle Wealth Management Advisory Group’s portfolio.

Other Hedge Funds, Including , Ropes Wealth Advisors boosted its stake in BMY in the latest quarter, The investment management firm added 12,014 additional shares and now holds a total of 67,473 shares of Bristol-Myers Squibb Co which is valued at $4.8 Million. Bristol-Myers Squibb Co makes up approx 2.13% of Ropes Wealth Advisors’s portfolio.Mufg Americas Holdings Corp boosted its stake in BMY in the latest quarter, The investment management firm added 11,287 additional shares and now holds a total of 233,706 shares of Bristol-Myers Squibb Co which is valued at $16.6 Million. Bristol-Myers Squibb Co makes up approx 0.59% of Mufg Americas Holdings Corp’s portfolio.Centre Asset Management reduced its stake in BMY by selling 3,070 shares or 23.13% in the most recent quarter. The Hedge Fund company now holds 10,200 shares of BMY which is valued at $726,444. Bristol-Myers Squibb Co makes up approx 0.13% of Centre Asset Management’s portfolio.Nordea Investment Management Ab reduced its stake in BMY by selling 58,983 shares or 21.25% in the most recent quarter. The Hedge Fund company now holds 218,595 shares of BMY which is valued at $15.8 Million. Bristol-Myers Squibb Co makes up approx 0.05% of Nordea Investment Management Ab’s portfolio.Mizuho Trust Banking Ltd. boosted its stake in BMY in the latest quarter, The investment management firm added 90,457 additional shares and now holds a total of 2,671,753 shares of Bristol-Myers Squibb Co which is valued at $192.8 Million. Bristol-Myers Squibb Co makes up approx 0.61% of Mizuho Trust Banking Ltd.’s portfolio.

Bristol-Myers Squibb Co opened for trading at $70.55 and hit $71.16 on the upside on Friday, eventually ending the session at $70.77, with a gain of 0.63% or 0.44 points. The heightened volatility saw the trading volume jump to 51,64,177 shares. Company has a market cap of $118,137 M.

On the company’s financial health, Bristol-Myers Squibb Co reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.65. The company had revenue of $4391.00 million for the quarter, compared to analysts expectations of $4268.65 million. The company’s revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.71 EPS.

Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Company shares were Reiterated by UBS on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 80 from a previous price target of $73 .Company shares were Reiterated by Barclays on Apr 29, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 75 from a previous price target of $70 .Societe Generale Initiated Bristol-Myers Squibb Co on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $48.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.

Leave a Reply

Bristol-Myers Squibb Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bristol-Myers Squibb Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.